May 03, 2021
According to the business intelligence report titled ‘GLOBAL Human Microbiome Market 2019-2027’, available with Market Study Report LLC, global human microbiome market is expected to register a healthy compound annual growth rate of 21.89% during the analysis period of 2019-2027.
Increasing development of human microbiome-based drugs and diagnostics tools coupled with introduction of advanced precision medicines are fueling global human microbiome market growth.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2487085/
Rising prevalence of chronic ailments such as diabetes, cardiovascular diseases, and cancer, innovative product launches, increasing disposable incomes, and strategic alliances among industry leaders are further propelling the industry expansion.
For the record, microbiome refers to the term used to define the genes of microbes including viruses, protozoa, fungi, and bacteria. The human body hosts a multitude of microorganism species, predominantly present in the gut.
The report states that favorable government as well as private investments towards disease detection along with growing emphasis on early diagnosis and detection of diseases are positively swaying global human microbiome market dynamics.
On the contrary, dearth of skilled and technologically adept workers along with lack of awareness regarding human microbiome will continue to restrain the industry expansion throughout the stipulated timeframe.
From a geographical front, the market presence spans across Europe, North America, Asia-Pacific, and rest of the world.
Among these, North America human microbiome market is predicted to grow significantly through 2027, owing to escalating private as well as government investments and increasing research & development activities by research institutes and companies.
The Asia-Pacific marketplace is also expected to amass substantial gains during the analysis timeframe, on account of favorable funding towards development of human microbiome as well as precision medicines.
Emphasizing on competitive landscape, 4D Pharma plc, Actogenix N.V., Ritter Pharmaceuticals Inc., Enterome SA, MiOmics Inc., Microbiome Therapeutics LLC, Rebiotix Inc., Symbiotix Biotherapies Inc., Second Genome Inc., Avidbiotics Inc., Vedanta Biosciences Inc., Metabiomics Corp., Avidbiotics Corporation, Osel Inc., Metabogen AB, and Symberix Inc. are the prominent organizations defining global human microbiome market trends.